Mirikizumab (Omvoh)

Key Messages

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses Mirikizumab (Omvoh) is available in 3 different dosing forms:
  • prefilled syringe — 100 mg/1 mL SC
  • autoinjector pen — 100 mg/1 mL SC
  • vial — 300 mg/15 mL IV.
• Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, had a loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase inhibitor